MedTrace Logo

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

NCT00934076 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-05-08

No results posted yet for this study

Summary

The purpose of this study the safety and effectiveness of oral AT-101 when given with the standard dose of erlotinib (Tarceva)to patients who are older that 18 and who have advanced non-small cell lung cancer, who have relapsed or progressed on prior platinum-based chemotherapy.

It is proposed that the effects of AT-101 may improve the clinical benefit of erlotinib in patients with advanced NSCLC.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

Tarceva plus AT-101

150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles. Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis.

Sponsors & Collaborators

  • Ascenta Therapeutics

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Francisco Robert, M.D. · University of Alabama at Birmingham

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-01-31
Completion
2015-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00934076 on ClinicalTrials.gov